NASDAQ:SPRY ARS Pharmaceuticals (SPRY) Stock Price, News & Analysis $9.94 +0.15 (+1.53%) Closing price 09/23/2025 04:00 PM EasternExtended Trading$9.96 +0.02 (+0.15%) As of 09/23/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About ARS Pharmaceuticals Stock (NASDAQ:SPRY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ARS Pharmaceuticals alerts:Sign Up Key Stats Today's Range$9.81▼$10.1250-Day Range$9.41▼$18.3552-Week Range$9.38▼$18.90Volume1.65 million shsAverage Volume3.16 million shsMarket Capitalization$982.33 millionP/E RatioN/ADividend YieldN/APrice Target$32.50Consensus RatingBuy Company Overview ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California. Read More ARS Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreSPRY MarketRank™: ARS Pharmaceuticals scored higher than 55% of companies evaluated by MarketBeat, and ranked 498th out of 946 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.8 / 5Analyst RatingBuy Consensus RatingARS Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Upside PotentialARS Pharmaceuticals has a consensus price target of $32.50, representing about 227.0% upside from its current price of $9.94.Amount of Analyst CoverageARS Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about ARS Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for ARS Pharmaceuticals are expected to grow in the coming year, from ($0.55) to ($0.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ARS Pharmaceuticals is -20.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ARS Pharmaceuticals is -20.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioARS Pharmaceuticals has a P/B Ratio of 3.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ARS Pharmaceuticals' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted36.05% of the float of ARS Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverARS Pharmaceuticals has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.Change versus previous monthShort interest in ARS Pharmaceuticals has recently increased by 18.40%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldARS Pharmaceuticals does not currently pay a dividend.Dividend GrowthARS Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted36.05% of the float of ARS Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverARS Pharmaceuticals has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.Change versus previous monthShort interest in ARS Pharmaceuticals has recently increased by 18.40%, indicating that investor sentiment is decreasing significantly. News and Social Media3.2 / 5News Sentiment0.68 News SentimentARS Pharmaceuticals has a news sentiment score of 0.68. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for ARS Pharmaceuticals this week, compared to 6 articles on an average week.Search Interest8 people have searched for SPRY on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.MarketBeat Follows2 people have added ARS Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ARS Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,533,760.00 in company stock.Percentage Held by Insiders33.50% of the stock of ARS Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions68.16% of the stock of ARS Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ARS Pharmaceuticals' insider trading history. Receive SPRY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ARS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SPRY Stock News HeadlinesARS Pharmaceuticals: A Significant Upside Is Expected From neffySeptember 23 at 3:01 AM | seekingalpha.comARS Pharmaceuticals announces neffy approved in JapanSeptember 19, 2025 | msn.comChina’s message to TrumpDid China just fire shots at America? Last week, in Tiananmen Square, China put on a chilling display of military power. Fighter jets, tanks, AI-guided drones — all paraded under the red flag, in front of Vladimir Putin, Kim Jong Un, and more than two dozen world leaders. | Porter & Company (Ad)ARS Pharmaceuticals stock rises after Japan approves needle-free epinephrine spraySeptember 19, 2025 | investing.comneffy® (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)September 19, 2025 | finance.yahoo.comARS Pharmaceuticals and Alfresa Holdings Receive Japanese Approval for neffy® Epinephrine Nasal Spray to Treat AnaphylaxisSeptember 19, 2025 | quiverquant.comQARS Pharmaceuticals, Inc. (SPRY): A Bull Case TheorySeptember 18, 2025 | finance.yahoo.comARS Pharmaceuticals, Inc. (SPRY): A Bull Case TheorySeptember 18, 2025 | msn.comSee More Headlines SPRY Stock Analysis - Frequently Asked Questions How have SPRY shares performed this year? ARS Pharmaceuticals' stock was trading at $10.55 at the beginning of the year. Since then, SPRY shares have decreased by 5.8% and is now trading at $9.94. How were ARS Pharmaceuticals' earnings last quarter? ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) announced its earnings results on Wednesday, August, 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.41) by $0.05. The firm had revenue of $15.72 million for the quarter, compared to analysts' expectations of $12.92 million. ARS Pharmaceuticals had a negative trailing twelve-month return on equity of 21.85% and a negative net margin of 42.74%. Read the conference call transcript. Who are ARS Pharmaceuticals' major shareholders? Top institutional shareholders of ARS Pharmaceuticals include Alliancebernstein L.P. (3.90%), Franklin Resources Inc. (1.86%), Adage Capital Partners GP L.L.C. (1.76%) and Aberdeen Group plc (1.53%). Insiders that own company stock include Ra Capital Management, LP, Sarina Tanimoto, Richard E Lowenthal, Laura Shawver, Justin Chakma, Alexander A Fitzpatrick, Eric Karas, Kathleen D Scott, Brian Dorsey, Peter A Thompson and Brent L Saunders. View institutional ownership trends. How do I buy shares of ARS Pharmaceuticals? Shares of SPRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ARS Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ARS Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), Voyager Therapeutics (VYGR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings8/13/2025Today9/23/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SPRY CIK1671858 Webars-pharma.com Phone206-456-2900FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Price Target for ARS Pharmaceuticals$32.50 High Price Target$40.00 Low Price Target$27.00 Potential Upside/Downside+227.0%Consensus RatingBuy Rating Score (0-4)3.14 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.49) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$8 million Net Margins-42.74% Pretax Margin-42.49% Return on Equity-21.85% Return on Assets-15.88% Debt Debt-to-Equity Ratio0.37 Current Ratio6.17 Quick Ratio5.98 Sales & Book Value Annual Sales$89.15 million Price / Sales11.02 Cash FlowN/A Price / Cash FlowN/A Book Value$2.64 per share Price / Book3.77Miscellaneous Outstanding Shares98,830,000Free Float65,719,000Market Cap$982.37 million OptionableOptionable Beta0.88 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:SPRY) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIs This Nvidia’s Next Big Invention? (Picture Inside)Nvidia gave investors a chance to make more than 150 times their money with its AI chips known as graphic proc...InvestorPlace | SponsoredAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ARS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.